AmCad BioMed

Name

AmCad BioMed

Legal name

AmCad BioMed Corporation

Website

https://amcad.com.tw

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Medical Imaging AI Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Software Publishers (513210), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industries

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Imaging Informatics & Workflow (PACS/RIS/VNA) (HLAHABAI), Pulmonology & Sleep Medicine Telemedicine Platforms (HLALAGAF), Teleradiology Platforms & Reading Workflow (HLACALAK)

Keywords

• Ultrasound AI software
• Medical diagnostic imaging
• Thyroid ultrasound analysis
• Breast cancer screening
• Sleep apnea assessment

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Ultrasound AI Software Solutions: AmCad BioMed generates revenue through AI-powered ultrasound diagnostic software solutions. The company develops and licenses AI software that integrates with ultrasound systems to enhance diagnostic accuracy for thyroid, breast, and obstructive sleep apnea conditions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

AmCad BioMed develops and licenses AI-powered ultrasound software solutions that integrate with ultrasound imaging systems to enhance diagnostic accuracy. The portfolio includes four products: AmCAD-UO for obstructive sleep apnea (OSA) assessment, AmCAD-UT for thyroid ultrasound analysis, AmCAD-UB for breast ultrasound with BI-RADS classification, and AmCAD-US for soft tissue analysis across various organs.

Product overview

AmCad BioMed offers a suite of four AI-powered ultrasound software solutions designed to enhance diagnostic accuracy and streamline clinical workflows. The portfolio includes AmCAD-UO for obstructive sleep apnea assessment, AmCAD-UT for thyroid ultrasound examinations, AmCAD-UB for breast ultrasound with BI-RADS insights, and AmCAD-US for soft tissue analysis. All four products integrate artificial intelligence into ultrasound imaging to revolutionize patient diagnosis and treatment.

Differentiator

Problem solved

Functional benefit

Brands

• AmCAD-UO: AI-powered ultrasound solution for obstructive sleep apnea (OSA) assessment and treatment
• AmCAD-UT
• AmCAD-UB
• AmCAD-US

Products and services

• AmCAD-UO

Quantifiable outcome

• Up to 30% of thyroid nodules are indeterminate cases by conventional ultrasound interpretation
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Scale indicators3 records

Recent moves3 records

Expansion highlights5 records

Broad incumbents

• Hologic: Dominant incumbent in breast imaging and women's health ultrasound; directly relevant to AmCAD-UB given overlapping breast-imaging customers and BI-RADS workflows.
• Philips: Global imaging and ultrasound OEM with embedded AI capabilities and broad enterprise relationships that AmCad must either partner with or displace.
• Siemens Healthineers: Major imaging OEM with integrated AI in its ultrasound portfolio (e.g., AI-Rad, eSie Touch); competes as a bundled incumbent rather than a niche AI software vendor.
• GE HealthCare: Largest global ultrasound OEM, now selling bundled AI (including Caption Health); overlaps with AmCad's AI-ultrasound offering as a broad incumbent in the same installed base.

Direct peers

• Ultromics: AI echocardiography platform for cardiac diagnostics; comparable as an AI-ultrasound pure-play focused on improving diagnostic accuracy, albeit in a different organ specialty.
• Koios Medical: AI software for breast and thyroid ultrasound decision support, directly overlapping AmCad's AmCAD-UT and AmCAD-UB products in target indication, modality, and clinician user.
• Butterfly Network: AI-enabled handheld ultrasound platform with embedded AI for image acquisition and interpretation, comparable as a software-defined AI ultrasound company targeting similar clinical workflows.
• Caption Health (GE HealthCare): AI-guided ultrasound acquisition and interpretation, now part of GE HealthCare; competes head-to-head with AmCad's AI-ultrasound proposition across hospital and point-of-care settings.
• Delphinus Medical Technologies: AI-enabled breast ultrasound (SoftVue) for dense-breast cancer detection, directly comparable to AmCAD-UB's positioning in dense-breast screening.

Regional players

• Mindray: Asia-based medical device OEM with growing global ultrasound share and AI-enabled systems; comparable as a regional incumbent AmCad may partner with or compete against in APAC and emerging markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@AmCad
• Facebookfacebook.com/AmcadBiomed
• LinkedInlinkedin.com/company/amcad-biomed-corporation/mycompany

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AmCad BioMed